Lamhamedi-Cherradi et al. recently proposed AR as a novel therapeutic target in DSRCT and demonstrated the ability of the AR blocker enzalutamide and an AR-targeting anti-sense oligonucleotide to reduce DSRCT tumor growth in vivo10. This evidence concerns the gene AR and neoplasm.